Made for the UK. Informed by evidence.Our editorial promise
UPCOMING MEDICINES

Promising research. Open questions.

A selected tracker of obesity treatments still in development. A successful trial is a step in the evidence process; it does not establish UK authorisation, a launch date, a price or NHS funding.

Phase 3 · investigational

Retatrutide

Investigational GIP, GLP-1 and glucagon receptor agonist.

Latest event: 14 November 2026

What the evidence says so far

Lilly’s November 2026 update describes phase 3 research across obesity-related outcomes. Its October announcement explicitly says retatrutide has not been authorised by any regulator.

What remains uncertain

A future UK licence, final prescribing instructions, routine availability and NHS funding have not been established. Trial findings do not verify products offered by online sellers.

Follow the evidence

Sources & further reading

These links support the information above; they do not imply endorsement of this website.

  1. Lilly: November 2026 research update
  2. Lilly: October 2026 results and investigational status
Phase 3 · investigational

CagriSema

Investigational combination of the amylin analogue cagrilintide and GLP-1 receptor agonist semaglutide.

Latest event: 14 November 2026

What the evidence says so far

REDEFINE 9 adds evidence about lower doses. The manufacturer’s 14 November update continues to describe CagriSema as investigational.

What remains uncertain

The study does not establish the better active dose, superiority over other obesity medicines, a UK launch date or an NHS access route.

Follow the evidence

Sources & further reading

These links support the information above; they do not imply endorsement of this website.

  1. Novo Nordisk: REDEFINE 9 results and development status
Phase 3 · investigational

MariTide

Maridebart cafraglutide: an antibody–peptide conjugate that activates GLP-1 receptors and blocks GIP receptors.

Latest event: 3 November 2026

What the evidence says so far

Amgen’s 3 November 2026 update lists ongoing MARITIME-1 and MARITIME-2 weight-management trials, alongside studies of cardiovascular, sleep-apnoea and other outcomes. Less frequent dosing is being studied.

What remains uncertain

The final benefit–risk profile, any approved dosing interval, UK authorisation, price and NHS eligibility remain unestablished. A trial dosing schedule is not a licensed regimen.

Follow the evidence

Sources & further reading

These links support the information above; they do not imply endorsement of this website.

  1. Amgen: third-quarter 2026 pipeline update
  2. Amgen: MariTide mechanism and investigational status

Where do newly authorised tablets belong?

A treatment stops being “upcoming” in a country once it is authorised there, even if funding or launch questions remain. Our news pages explain the UK status of Wegovy tablets and Foundayo separately.

Read the UK access explainers →